Boston Scientific Corp., of Marlborough, Mass., has gained a green light from the U.S. FDA for its Vici Venous Stent system to treat iliofemoral venous obstructive disease. The approval was based on data from the VIRTUS study in 170 patients that evaluated the stent in relation to predefined objective performance goals in those with a clinically significant obstruction in the iliofemoral venous outflow tract.